Revenue segments as reported by the company.

Cardiovascular

Medical Surgical

Neuroscience

Diabetes

Other

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and development

Selling, general, and administrative

Amortization of intangible assets

Restructuring charges, net

Certain litigation charges, net

Other operating expense, net

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Medtronic

Medtronic Plc is a medical technology company, which engages in the development, manufacture, distribution, and sale of device-based medical therapies and services. It operates through the following segments: Cardiovascular Porrtfolio, Neuroscience Portfolio, Medical Surgical Portfolio, and Diabetes Operating Unit. The Cardiovascular Portfolio segment includes products for the diagnosis, treatment, and management of cardiac rhythm disorders and cardiovascular disease. The Neuroscience Portfolio is made up of cranial and spinal technologies, specialty therapies, and neuromodulation divisions. The Medical Surgical Portfolio is comprised of surgical innovations and respiratory, gastrointestinal, and renal divisions. The Diabetes Group segment offers insulin pumps, continuous glucose monitoring systems, and insulin pump consumables. The company was founded in 1949 and is headquartered in Dublin, Ireland.

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Earnings data Q1 2025

Earnings data Q2 2025

Medtronic reports strong Q4 results, anticipates margin pressures for FY '24

MDT reported strong Q4 results with organic revenue growth, but anticipates margin pressures and EPS decline for FY '24. They highlighted successful FDA approvals and expressed confidence in growth opportunities.

Medtronic reports strong Q2 earnings, highlights growth opportunities

Medtronic's Q2 earnings call showcased strong financial performance, with raised full-year guidance. The company emphasized growth in key business segments and highlighted opportunities in insulin-dependent patient solutions and AI-powered solutions. Challenges include delays in PMRI spend and minimal impact of GLP-1s on the business.

Medtronic exceeds Q3 expectations, focuses on growth and transformation

Medtronic's Q3 earnings call highlighted strong performance, raised outlook, and a focus on transformation for sustainable growth. The company is strategically addressing challenges through cost reduction efforts and seizing opportunities in key markets. Medtronic remains committed to driving innovation and maximizing shareholder value.

Medtronic exceeds Q4 expectations, eyes growth in innovative healthcare

Medtronic's Q4 performance showcased strong growth in key segments, with a focus on innovation and market expansion. Despite challenges from inflation and currency impact, the company remains optimistic about future growth opportunities driven by product advancements and strategic acquisitions.

Medtronic reports robust Q1 results, eyes growth amid challenges

Medtronic's Q1 performance showcased strong revenue growth and emphasized innovation across key business segments.
While facing challenges of growth deceleration and margin expansion, the company remains focused on operational efficiencies and market fundamentals.
Opportunities lie in bariatric space growth, ongoing transformation efforts, and advancements in diabetes programs and surgical systems.
Overall, Medtronic's strategic investments in technology, pricing strategies, and procedural trends position it for continued success and market leadership.

Medtronic surpasses revenue expectations, eyes growth in key markets

Medtronic delivered strong Q2 results with revenue growth ahead of expectations and raised full-year guidance. Despite concerns about GLP-1 drugs and the SELECT trial, the company remains optimistic about growth prospects, focusing on key markets and product innovation.

Medtronic reports solid Q3 growth, focuses on innovation and profitability

Medtronic's Q3 earnings call showcased strong financial performance, international market growth, and strategic decisions to drive innovation and profitability. The company's focus on new technologies, portfolio management, and overcoming challenges highlights a path towards sustained growth and earnings leverage. With positive progress in key business segments and a commitment to future profitability, Medtronic is well-positioned for continued success.

Medtronic reports robust Q4 growth, eyes operational efficiency and China

Medtronic's Q4 2024 earnings call highlighted strong revenue growth, new product launches, and a focus on restoring earnings power. The company provided guidance for fiscal year '25, expecting organic revenue growth, operating margin expansion, and non-GAAP diluted EPS. Analyst questions centered on EPS guidance, revenue growth drivers, and operational efficiencies.

Medtronic reports solid Q1 results, raises guidance for fiscal '25

Medtronic's Q1 2025 performance reflects steady revenue growth and increased EPS, driven by strong performances in key business segments and global markets.
The company's focus on innovation, strategic partnerships, and diversified revenue streams positions it well for future growth and market expansion.
While challenges exist in maintaining growth momentum and navigating market complexities, Medtronic's raised guidance and growth expectations signal confidence in its ability to drive top-line growth and restore earnings power.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Accenture Plc

Diageo

One of Diageo's biggest brands shares a very special symbol with the country of Ireland. Medtronic acquired an Irish company and then found the island a great place to settle.

3 Companies With Strong Irish Operations

Realty Income Corp

AT&T

As interest rates stay higher for longer, pushing traders towards fixed-income alternatives, dividend stocks return to investors' strategies after being sidelined for years. However, the terrain for dividend stocks has evolved, reflecting broader investment preferences and strategy shifts.

Dividend Deluge: 3 Stocks Showering Shareholders With Cash

Healthpeak Properties

“Higher for longer” may prove true as sticky inflation indicates the higher-rate environment might be here to stay. As interest rates stay steady, risk-averse investors gravitate towards short-term Treasuries for safety.

3 Stocks to Buy if the Fed Keeps Rates High for the Rest of 2024

Johnson & Johnson

Pfizer

Undervalued healthcare stocks are primed for a comeback this year, proving themselves as lucrative investments amidst a revitalized market. With a significant uptick in performance, the S&P 500 Health Care index soared roughly 7% year-to-date (YTD), marking a robust recovery from last year's challenges.

The 3 Most Undervalued Healthcare Stocks to Buy in March 2024

Becton, Dickinson and Co.

Globus Medical

Intuitive Surgical

Smith & Nephew

Stryker

Zimmer Biomet Hlds

There are some robotic surgery stocks for investors to buy in March this year. The growth of robotic-assisted surgery has been driven by its potential benefits, such as smaller incisions, reduced pain and scarring, quicker recovery times, and improved clinical outcomes.

7 Robotic Surgery Stocks to Buy for the Future of Healthcare

Medtronic plc (MDT) Management presents at 2024 Barclays 26th Annual Healthcare Conference (Transcript)

Aflac

Ameriprise Financial

Amphenol

Broadcom

Blackrock Inc

Caterpillar

Cummins

Fastenal

Hormel Foods

Hershey

Illinois Tool Works

Kroger

New Linde PLC

Lowe's

Mastercard

McCormick

Altria

Microsoft

Paychex

Packaging Corp of America

Starbucks

Tractor Supply

Texas Instruments

Dividend growth investors focus on consistently growing dividends rather than high yields, as it ensures income continues to grow over time. Dividend safety is often considered of utmost importance for an income investor; however, future dividend growth can pose a greater risk to meeting future goals. The dividend growth coverage ratio, which compares earnings growth to dividend growth, can help determine a company's ability to sustain dividend growth in the long run.

Rethinking Risk: Why It's Time To Shift Focus From Dividend Safety To Dividend Growth

Medtronic is a healthcare behemoth, developing and manufacturing medical devices for chronic diseases, with a broad and dominant portfolio of industry-leading products. The company has increased its dividend for 46 consecutive years, which qualifies Medtronic for its status as a vaunted Dividend Aristocrat. The 10-year dividend growth rate is a strong 9.8%, although more recent dividend raises have been in mid-single digits.

Medtronic: Undervalued Medical Devices Stock With Robust Demand And Strong Dividend Growth

Medtronic's (MDT) data from a recent study indicate that the MiniMed 780G system exceeds international targets for TIR and even brings patients closer to euglycemia.

Medtronic's (MDT) MiniMed 780G System Study Data Favorable

Ambev

AstraZeneca

Alibaba

Baidu

British American Tobacco

Anheuser-Busch InBev

GlaxoSmithKline

Imperial Brands PLC

JD.com

Kao Corp

Kone Oyj

Nestle SA

Omron Corp

Pernod Ricard SA

Reckitt Benckiser Group PLC

Our 3-step process focuses on wide-moat stocks (as per Morningstar's rating). We are only interested in those targets that are attractively valued in historical comparison. We share the heat map of the most investable candidates that may be worth your time for further analysis.

International Wide-Moat Stocks On Sale - The March 2024 Heat Map

Medical device maker Medtronic PLC NYSE: MDT is a Dividend Aristocrat in the medical and healthcare sectors. The medical device maker has raised its dividend payout for 46 consecutive years through bull and bear markets.

Medtronic is a Dividend Aristocrat That Keeps Gaining

New data presented at ATTD demonstrates the system's ability to help individuals with type 1 diabetes exceed international targets on outcome measures DUBLIN and FLORENCE, Italy , March 9, 2024 /PRNewswire/ -- Medtronic plc. (NYSE: MDT), a global leader in healthcare technology, today shared a robust set of new clinical and real-world evidence on the MiniMed™ 780G system from around the world including the largest set of data from early users in the United States.

New real-world data shows MiniMed™ 780G system sustains strong global performance, exceeding international targets for diabetes management

DexCom

Medtronic is a leading medical device maker that continues to get bigger and more diversified. DexCom's continuous glucose monitoring devices are crucial for diabetics, enabling strong growth.

2 Medical Device Stocks to Buy Hand Over Fist in March

Board authorizes $5 billion for share repurchases DUBLIN , March 7, 2024  /PRNewswire/ -- The board of directors of Medtronic plc (NYSE: MDT) on Thursday, March 7, 2024, approved the company's cash dividend for the fourth quarter of fiscal year 2024 of $0.69 per ordinary share. This quarterly declaration is consistent with the dividend announcement made by the company in May 2023.

Medtronic announces cash dividend for fourth quarter of fiscal year 2024

Charles River Laboratories

Stock markets are reaching new highs and exuberance is in the air. For value investors, this might seem like a perplexing time.

The Top 3 Healthcare Stocks to Buy in March 2024

DUBLIN , March 5, 2024 /PRNewswire/ -- Medtronic plc (NYSE:MDT), a global leader in healthcare technology, today announced it will participate in the 26th annual Barclays global healthcare conference on Tuesday, March 12, 2024. Karen Parkhill, Medtronic executive vice president and chief financial officer, will answer questions on the company beginning at 8:00 a.m.

Medtronic EVP & CFO Karen Parkhill to participate in the Barclays healthcare conference

Medtronic is the world's largest medical device company, and it has a 46-year streak of consecutive annual dividend raises. Cigarette sales are steadily declining, but Altria Group's bottom line keeps on climbing.

3 High-Yield S&P 500 Dividend Stocks Down More Than 28% to Buy Now and Hold at Least a Decade

Medtronic MDT (NYSE: MDT) recently reported its Q3 fiscal 2024 results (fiscal ends in April), with revenues and earnings beating the street estimates. The company reported revenue of $8.1 billion and adjusted earnings of $1.30 per share compared to the consensus estimates of $7.9 billion and $1.26, respectively.

What's Next For Medtronic Stock After An Upbeat Q3?

DUBLIN , Feb. 29, 2024 /PRNewswire/ -- Medtronic (NYSE:MDT), the global leader in healthcare technology, today announced it filed a complaint with the U.S. International Trade Commission (ITC), along with a parallel action in U.S. District Court for the District of Delaware, to block Axonics from improperly importing and selling products that infringe two Medtronic patents related to the MRI compatibility of implantable medical devices. "Medtronic is continuing our efforts to stop Axonics from profiting off of their unauthorized use of our innovations and intellectual property," said Mira Sahney, president of the pelvic health business in the neuroscience portfolio at Medtronic.

Medtronic files ITC action against Axonics to stop unauthorized use of Medtronic innovations

Thesis & Performance: Previous analysis suggested a fair price of $137.6; Q3 2024 earnings beat estimates, affirming my "strong buy" recommendation. Financial Overview: Q3 2024 earnings reported revenue of $8.1B and EPS of $1.30, surpassing estimates, with steady growth in net income despite segment year-to-date underperformance. Two valuation models presented: analyst estimates suggests a $178.12 fair price (107.5% upside), meanwhile the conservative model projects a $126.09 fair price (46.9% upside).

Medtronic: Its Recent Beat Proves That It Continues To Be A Rock

News for Medtronic Stock (MDT)